10,914 Shares in Intuitive Surgical, Inc. $ISRG Acquired by Plato Investment Management Ltd

Plato Investment Management Ltd acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 10,914 shares of the medical equipment provider’s stock, valued at approximately $4,315,000.

A number of other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after buying an additional 731 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Intuitive Surgical by 3.8% during the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Intuitive Surgical by 38.0% in the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 268 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in Intuitive Surgical in the second quarter valued at about $200,000. Finally, Main Street Financial Solutions LLC increased its position in Intuitive Surgical by 92.4% in the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock worth $1,592,000 after purchasing an additional 1,407 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the transaction, the executive vice president owned 5,320 shares in the company, valued at approximately $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. The trade was a 46.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 17,088 shares of company stock valued at $6,941,913. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen cut Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Saturday. Barclays set a $651.00 price target on shares of Intuitive Surgical and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Oppenheimer raised shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price target for the company in a research note on Wednesday, August 12th. Truist Financial cut their price objective on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research note on Monday, July 20th. Twenty-two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $508.68.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $394.51 on Monday. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The business’s 50-day moving average price is $391.45 and its two-hundred day moving average price is $440.66. The firm has a market capitalization of $139.37 billion, a price-to-earnings ratio of 45.19, a PEG ratio of 2.85 and a beta of 1.47.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. The firm had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.81 earnings per share. Sell-side analysts predict that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.